Zymeworks (NYSE:ZYME) will install Ken Galbraith as chairman and CEO, replacing the company’s outgoing leader Ali Tehrani on or before February 1. Galbraith has more than 30 years of experience working in life sciences, venture capital and global commercialization. “Ken Galbraith is an outstanding global leader who brings more than 30 years of life science…
Zymeworks and its partner BeiGene expand zanidatamab pivotal trial in Asia
Zymeworks (NYSE:ZYME) and its collaborator BeiGene have announced the dosing of the first patient with zanidatamab (ZW25) in South Korea–based HERIZON-GEA-01 study. The study will focus on patients with advanced or metastatic HER2-positive gastroesophageal adenocarcinomas. As a result of the development, Zymeworks will receive an $8 million development milestone payment from BeiGene. Zymeworks and BeiGene plan to…
Zymeworks is using a platform approach for biotherapeutics
Focused on antibody-based cancer therapies, Zymeworks (NYSE:ZYME) believes bi- and multi-specific antibodies offer significant potential in oncology. Such therapies could provide new biological avenues for cancer treatment and extend immunotherapy to patients with few options. The FDA has approved three bispecific antibodies, and more than one hundred others are in development across the industry. Zymeworks…